PVI

CathVision to Present Predictive Filtering Capabilities of ECGenius System at EHRA 2024

Retrieved on: 
Monday, April 8, 2024
Ghent University, Freedom, PVI, Noise, Vein, Patient, University, EP, Artifact, PV, Extended play, Electronics

COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ -- CathVision today announced data from the PVISION trial demonstrating the ability of the ECGenius System's predictive noise filter to increase the time window before noise saturates PV potentials during PVI procedures. The data will be presented in a poster presentation at EHRA 2024.1

Key Points: 
  • COPENHAGEN, Denmark, April 8, 2024 /PRNewswire/ -- CathVision today announced data from the PVISION trial demonstrating the ability of the ECGenius System's predictive noise filter to increase the time window before noise saturates PV potentials during PVI procedures.
  • Key data points include:
    Of the 68 veins treated, 33 exhibited power line noise on one or more bipolar traces during the freeze cycle (49%).
  • "When we employed the predictive filter using the ECGenius System, the noise was eliminated from the electrogram data during the PVI procedure.
  • For more information about ECGenius System and CARDIALYTICS, or to meet with CathVision at EHRA 2024, please contact us and connect on LinkedIn .

AM Best Affirms Credit Ratings and Assigns National Scale Rating to PVI Insurance Corporation

Retrieved on: 
Wednesday, March 27, 2024
Banking, Professional Services, Insurance, Finance, PVI, ERM, HDI, Risk management, Communication, ALL, News, Aviation, Petrovietnam, NSR, Credit, Investment, AM Best, Engineering

AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of PVI Insurance Corporation (PVI Insurance) (Vietnam).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of PVI Insurance Corporation (PVI Insurance) (Vietnam).
  • Additionally, AM Best has assigned the Vietnam National Scale Rating (NSR) of aaa.VN (Exceptional) to PVI Insurance with a stable outlook.
  • The ratings factor in rating enhancement from PVI Insurance’s ultimate parent, HDI Haftpflichtverband der Deutschen Industrie V.a.G.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .

Global Guidewires (Nitinol, Stainless Steel, Others) Market Report 2024: Analysis & Forecasts 2019-2022 and 2023-2029 - Minimally Invasive Techniques Expand, Boosting Guidewire Utilization - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Health, Medical Supplies, Medical Devices, Disease, PVI, Friction, ERCP, Coronary artery disease, Conditional sentence, Bacteria, Epidemiology, Specialization, Risk, Investment, Infection, Patient safety, USD, Surgery, Non-communicable disease, Cardiovascular disease, Fungal infection, Obesity, Biotechnology, Peripheral artery disease, Porter's five forces analysis, Diabetes, Chlorhexidine, World Health Organization, Safety, Fatigue, Hypertension, Cardiology, Neurology, Urology, Prevalence, Death, PCI, Diagnosis, Arrhythmia, Temperature, Growth, Incidence, Anatomy, SWOT, Mortality, Stainless steel, WHO, Nickel titanium, Physician, Medical imaging

Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.

Key Points: 
  • Guidewires Market is being propelled increasing prevalence of cardiovascular diseases, technological advancements in guidewire design and materials, rising demand for minimally invasive procedures, and expanding healthcare infrastructure in developing economies.
  • As the prevalence of risk factors such as obesity, diabetes, and hypertension increase, so does the incidence of cardiovascular diseases.
  • Guidewires are essential tools in percutaneous coronary interventions (PCI), peripheral vascular interventions (PVI), and electrophysiology procedures, driving the demand for guidewires.
  • The increasing prevalence of chronic diseases worldwide drives the demand for guidewires by necessitating minimally invasive interventions for diagnosis and treatment.

Engage USA Leases 40,000 SF at 200 Monroe Avenue in Frederick

Retrieved on: 
Tuesday, February 13, 2024
SF, Database, Family, PVI, Property management

FREDERICK, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Ruppert Properties announced today that the company has completed a new lease with Engage USA for 40,000 square feet at 200 Monroe Avenue in Frederick, MD.

Key Points: 
  • FREDERICK, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ -- Ruppert Properties announced today that the company has completed a new lease with Engage USA for 40,000 square feet at 200 Monroe Avenue in Frederick, MD.
  • "We are so excited to be joining the Monroe Avenue community and are really looking forward to growing our relationships with neighboring tenants and Ruppert as we settle in."
  • "We are so excited to be joining the Monroe Avenue community and are really looking forward to growing our relationships with neighboring tenants and Ruppert as we settle in", stated Kathleen Clem, President of Engage USA.
  • Engage USA joins Image Direct and PVI Office Furniture in the 134,000 SF industrial building that is now 100% leased.

Data Demonstrating vMap’s Impact on Atrial Fibrillation Treatment Outcomes Unveiled at AF Symposium 2024

Retrieved on: 
Thursday, February 1, 2024
Cardiology, Biotechnology, General Health, Health, Medical Devices, Hospitals, Health Technology, Clinical Trials, Arrhythmia, PVI, Vektor, Atrial flutter, Patient, Medicine, Artificial intelligence, Physician, Vector, Machine learning, Algorithm, Medical device

Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, will release findings today at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by Machine Learning in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes.

Key Points: 
  • Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, will release findings today at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by Machine Learning in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes.
  • The study demonstrates how non-pulmonary vein AF driver ablation guided by vMap could improve ablation outcomes for patients with persistent AF, recurrent AF after prior ablation, or AF associated with atrial flutter or focal AT.
  • Following PVI, the study group (n=27) had ablation of 1.6 ± 0.7 additional AF driver sites identified by vMap’s artificial intelligence-based analysis.
  • During ablation, 15 patients in the study group had driver site ablation during ongoing AF or focal AT resulting in atrial termination in 80% of such cases.

CathVision to Showcase ECGenius System and AI Algorithms at AF Symposium 2024

Retrieved on: 
Tuesday, January 30, 2024
Signal, EP, Workflow, PVI, AI, University, Electrophysiology, Noise, Extended play, Acquisition, Algorithm

COPENHAGEN, Denmark, Jan. 30, 2024 /PRNewswire/ -- CathVision today announced the ECGenius™ System will be featured in a Spotlight Session led by Dr. Larry Chinitz at the 29th Annual International AF Symposium in Boston, February 1-3, and highlighted at the CathVision booth (#419).1

Key Points: 
  • He will detail his experiences with CathVisions's advanced EP recording system, discussing how the acquisition of high-fidelity, low-noise cardiac electrograms create the necessary foundation to implement intelligent, automated analyses provided by the CARDIALYTICS™ AI algorithms.
  • "AI in the EP Lab: Replacing Legacy EP Recording Standards with ECGenius and AI-Algorithms to Effectively Measure Success of Ablation Outcomes"
    Reinforcing the benefits of the ECGenius System, two poster presentations will also be shared during the AF Symposium featuring data from studies conducted at the University of Vermont.
  • ECGenius System and our CARDIALYTICS AI algorithms deliver the quality and streamlined processes to capture, assess, and ablate confidently."
  • For more information about ECGenius System and CARDIALYTICS, or to meet with CathVision at the AF Symposium, please contact us and connect on LinkedIn .

Partners Value Investments Announces Initial Preferred Distributions and Dividend Rate on Preferred Shares

Retrieved on: 
Wednesday, December 13, 2023
TSX Venture Exchange, PVI, Security (finance)

TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Partners Value Investments L.P. (TSXV: PVF.UN, PVF.PR.U) (“PVI LP”) and Partners Value Investments Inc. (TSXV: PVF.WT, PVF.PR.V) (“PVII”) today jointly announce the following expected initial distributions on the Class A preferred units, Series 1, 2, 3 and 4 of PVI LP and Class A preferred shares, Series 1 of PVII.

Key Points: 
  • TORONTO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Partners Value Investments L.P. (TSXV: PVF.UN, PVF.PR.U) (“PVI LP”) and Partners Value Investments Inc. (TSXV: PVF.WT, PVF.PR.V) (“PVII”) today jointly announce the following expected initial distributions on the Class A preferred units, Series 1, 2, 3 and 4 of PVI LP and Class A preferred shares, Series 1 of PVII.
  • Unitholders of PVI LP and shareholders of PVII of record at December 29, 2023 will receive the distributions on January 31, 2024.
  • The dividend rate for the Class A preferred shares, Series 1 of PVII (the “Preferred Shares”) is 4% per annum equal to
    $0.01 per Preferred Share each quarter, rather than $0.04 per Preferred Share each quarter.
  • Holders of Preferred Shares are entitled to receive an annual dividend of $0.04 per Preferred Share payable quarterly.

Medtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation

Retrieved on: 
Wednesday, December 13, 2023
St Davids, Research, Safety, NYSE, Cryoablation, Medical Center, Chosen-ciphertext attack, Medtronic, Patient, PVI, European, FDA, CE, Atrial fibrillation, PFA, Cryo, MD, Diagnosis, Phrenic nerve, Learning curve, Catheter, Electrode, EP, SVP, Cosmetics, Medical device

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.

Key Points: 
  • This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
  • "Launching the first FDA-approved PFA technology is not just a milestone; the PulseSelect PFA system is setting a new standard in safety for AF ablation with excellent efficacy and efficiency1.
  • The learning curve in using the catheter and system is short, and the catheter enables the operator to deliver fast and controlled pulsed field energy for AF ablation."
  • The PulseSelect PFA system also includes the following:
    Designed as a plug-and-play system, PulseSelect can be used with any mapping system or with just fluoroscopy2.

CathVision Unveils ECGenius 3.1 To Improve Workflows and Optimize EGM AI Analyses

Retrieved on: 
Tuesday, December 12, 2023
NYU Langone Health, ECG, Acquisition, Q3, Signal, PVI, Algorithm, Workflow, Intelligence, Software, Diagnosis, AI, Physician, Noise, EP, Medical imaging, Electrophysiology

COPENHAGEN, Denmark, Dec. 12, 2023 /PRNewswire/ -- CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the launch of ECGenius 3.1, an advanced version of the ECGenius™ System software. The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.1

Key Points: 
  • The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.1
    Intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.
  • ECGenius 3.1 delivers several new and enhanced features to provide an improved user experience throughout, including:
    The release of ECGenius 3.1 follows the Q3 launch of the PVI Analyzer™ and Signal Complexity™ algorithms.
  • ECGenius 3.1 makes the workflow transition seamless and strengthens our leadership position in equipping electrophysiologists with the technology necessary to elevate patient outcomes."
  • With exceptional data from the ECGenius System, intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.

New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Elderly Patients Undergoing Gastrointestinal Surgery

Retrieved on: 
Monday, August 21, 2023
Research, Surgery, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Health, Science, Pulse, Infection, Therapy, Splenic infarction, Multimedia, CFT, PPV, Vomiting, PVI, MASI, Patient, SVV, Perioperative medicine, Ageing, Arrhythmia, Pulmonary edema, Fasting, Pneumonia, Medical imaging

stroke volume variation [SVV] and pulse pressure variation [PPV]), of being obtained via noninvasive Masimo rainbow SET® pulse oximetry and Pulse CO-Oximetry.

Key Points: 
  • stroke volume variation [SVV] and pulse pressure variation [PPV]), of being obtained via noninvasive Masimo rainbow SET® pulse oximetry and Pulse CO-Oximetry.
  • PVi is indicated as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.
  • Patients were randomly assigned to the GDFT group (n = 107) or the conventional fluid therapy (CFT) group (n = 104).
  • In the GDFT group, fluid therapy was guided by PVi obtained from the photoplethysmographic waveform measured by fingertip rainbow® Pulse CO-Oximetry sensors.